Zanubrutinib: past, present, and future.

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Bruton tyrosine kinase (BTK) inhibitors have revolutionized B-cell malignancy treatment, with ibrutinib as a pioneering therapy.
• Chemo-immunotherapies were the standard before BTK inhibitors, offering limited efficacy and safety.
• Understanding BTK's role is crucial for developing targeted therapies.

Purpose of the Study:

• To review the development of zanubrutinib, a next-generation BTK inhibitor.
• To highlight its molecular design, preclinical advantages, and clinical efficacy.
• To showcase advancements in B-cell malignancy treatment.

Main Methods:

• Structure-activity relationship strategy for molecular design.
• Preclinical studies assessing specificity, enzymatic, and pharmacokinetic properties.
• Clinical trials evaluating safety and efficacy in B-cell malignancies.

Main Results:

• Zanubrutinib demonstrated superior specificity and bioavailability compared to ibrutinib in preclinical studies.
• Clinical trials showed significant activity and an improved safety profile in B-cell malignancies.
• Zanubrutinib is now approved for various B-cell malignancies globally.

Conclusions:

• Zanubrutinib represents a significant advancement in BTK inhibitor therapy for B-cell malignancies.
• Its development underscores the importance of multidisciplinary research from bench to bedside.
• Continued research explores zanubrutinib's potential in combination therapies and other hematologic conditions.